Bioteque (ROCO:4107) EBIT: NT$695 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4107 Bioteque Corp ROCO:4107
84 GF Score
Price NT$114.50
GF Value NT$130.19
Valuation Modestly Undervalued
View Full Analysis

What is Bioteque EBIT?

Bioteque ROCO:4107 +0.44% 84 EBIT is NT$695 Mil as of Mar. 2026. GuruFocus rates ROCO:4107 with a GF Score™ of 84/100 and a GF Value™ of NT$130.19 (Modestly Undervalued).

Bioteque's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was NT$186 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was NT$695 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bioteque's annualized ROC % for the quarter that ended in Mar. 2026 was 21.28%. Bioteque's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 30.71%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Bioteque's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 10.42%.


Bioteque  (ROCO:4107) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bioteque's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=704.052 * ( 1 - 21.2% )/( (2657.993 + 2555.406)/ 2 )
=554.792976/2606.6995
=21.28 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4659.999 - 334.478 - ( 1667.528 - max(0, 546.665 - 2332.7+1667.528))
=2657.993

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4805.862 - 765.568 - ( 1797.314 - max(0, 972.549 - 2457.437+1797.314))
=2555.406

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Bioteque's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=742.624/( ( (2309.886 + max(197.811, 0)) + (2328.701 + max(-262.167, 0)) )/ 2 )
=742.624/( ( 2507.697 + 2328.701 )/ 2 )
=742.624/2418.199
=30.71 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(243.683 + 294.358 + 48.315) - (334.478 + 0 + 54.067)
=197.811

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(218.121 + 299.839 + 47.369) - (765.568 + 0 + 61.928)
=-262.167

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Bioteque's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=695.154/6669.363
=10.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioteque EBIT Related Terms


Bioteque EBIT Historical Data

* Premium members only.

The historical data trend for Bioteque's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioteque EBIT Chart

Bioteque Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 540.09 627.50 581.12 687.74 682.16

Bioteque Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 172.66 136.18 178.66 194.66 185.66

ROCO:4107 vs ISRG, BDX, MDLN: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Bioteque's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioteque EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bioteque's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bioteque's EV-to-EBIT falls into.


ROCO:4107
84GF Score
Bioteque Corp ROCO:4107
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioteque EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$695 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$695 Mil mean?
Bioteque (ROCO:4107) has a EBIT of NT$695 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bioteque.
Is Bioteque's EBIT too high?
Bioteque's current EBIT is NT$695 Mil. Overall, Bioteque has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioteque's EBIT compare to ISRG and BDX?
Bioteque's EBIT of NT$695 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bioteque. Bioteque's current EBIT is NT$695 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioteque stock overvalued right now?
Based on GuruFocus' analysis, Bioteque (ROCO:4107) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$130.19, compared to a current price of NT$114.50 — trading 12.1% below its estimated fair value. The current EBIT is NT$695 Mil. Bioteque's overall GF Score™ is 84/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Bioteque (ROCO:4107), the current EBIT is NT$695 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioteque (ROCO:4107) Overvalued in 2026?

Based on GuruFocus' analysis, Bioteque stock appears to be undervalued. The current stock price of NT$114.50 is trading 12.1% below its estimated GF Value™ of NT$130.19. GuruFocus considers Bioteque to be Modestly Undervalued.

Key valuation signals for ROCO:4107:

  • EBIT: NT$695 Mil
  • GF Value™: NT$130.19 vs. price of NT$114.50 (12.1% below fair value)
  • GF Score™: 84/100

No single metric tells the full story. See the ROCO:4107 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bioteque Business Description

Address Chang-An E. Road, 5th Floor-6, No.23, Section 1, Taipei, TWN, 104
Bioteque Corp is engaged in manufacturing, trading, and selling medical equipment and instruments. The company operates in different segments such as Manufacturing medical disposables for hemodialysis use, and selling them to dealers and retailers; Manufacturing and selling catheters for healthcare and medical PVC IV bags to medical organizations; Manufacturing and selling medical key components and inner catheters to the medical organization; and Other segment. Geographically, the company generates a majority of its revenue from Asia and the rest from North America, South America, and other regions.
84GF Score

Get the complete analysis for ROCO:4107

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$114.50
Price
NT$130.19
GF Value